20.04.20: Start of Quiet Period
Start of Quiet PeriodLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 19, 2020 Category: Pharmaceuticals Source Type: news
27.04.20: Q1 2020 Investor Conference Call
Q1 2020 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 14, 2020 Category: Pharmaceuticals Source Type: news
08.04.20: Not intended for U.S. and UK Media
Bayer launches pre-filled syringe to administer eye medication Eylea® in Europemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 8, 2020 Category: Pharmaceuticals Source Type: news
08.04.20: Not intended for U.S. and UK Media
Bayer launches pre-filled syringe to administer eye medication Eylea™ in Europemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 7, 2020 Category: Pharmaceuticals Source Type: news
30.03.20: Not intended for U.S. and UK Media
Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancerOral androgen receptor inhibitor (ARi) Nubeqa® (darolutamide) approved for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease / Approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free survival (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profilemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 2, 2020 Category: Pharmaceuticals Source Type: news
29.03.20: Not intended for U.S. and UK Media - New study results add to solid evidence for the efficacy and safety of Rivaroxaban in the prevention of venous thromboembolism:
Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgeryData from PRONOMOS study published in The New England Journal of Medicine and presented during a virtual session of the American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual) / The first study to demonstrate that a Factor Xa inhibitor was superior to enoxaparin in reducing risk of major venous thromboembolism in adult patients who have undergone lower limb nonmajor orthopaedic surgery / Bleeding rates were low and not significantly different be...
Source: Bayer IR Newsfeed: Events - March 28, 2020 Category: Pharmaceuticals Source Type: news
28.03.20: Not intended for U.S. and UK Media - Data from Phase III VOYAGER PAD study published in The New England Journal of Medicine and presented during the American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology
Xarelto™ 2.5 mg plus aspirin significantly lowered the combined risk of limb ischemia and major cardiovascular events in patients with symptomatic peripheral artery disease post revascularizationThe only clinical outcome study to demonstrate the benefits of a combined antithrombotic and anti-platelet therapy in these vulnerable patients who currently have limited treatment options / Risk of acute limb ischemia was significantly reduced by 33% in these patients compared to those receiving aspirin alone / There was no significant increase in TIMI major bleeding, the principal safety outcome of the trialmehr ... (Source...
Source: Bayer IR Newsfeed: Events - March 27, 2020 Category: Pharmaceuticals Source Type: news
28.03.20: Not intended for U.S. and UK Media - Data from Phase III VICTORIA study presented at American College of Cardiology's 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC)
Vericiguat significantly reduced the risk of the composite primary endpoint of cardiovascular death or heart failure hospitalizationVICTORIA is the first positive contemporary outcomes study focused exclusively on a chronic heart failure patient population following a worsening event / Treatment effect on the composite endpoint of cardiovascular death or heart failure hospitalization was consistently demonstrated regardless of background heart failure therapy / Vericiguat was well-tolerated - overall incidence rate of adverse events was comparable to placebo / Studied in a population with higher event rates than in other c...
Source: Bayer IR Newsfeed: Events - March 27, 2020 Category: Pharmaceuticals Source Type: news
27.03.20: Coronavirus pandemic:
Bayer planning to hold online-only stockholders' meeting on April 28, 2020Stockholders able to exercise right to submit questions and cast votes in a timely manner / Online stockholders' meeting enables proposed dividend of 2.80 euros per share for 2019 to be paid on time and in full / Baumann: "Reliability for our stockholders is very important, especially during the crisis"mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 26, 2020 Category: Pharmaceuticals Source Type: news
24.03.20: Bayer's due diligence procedures for M&A transactions are appropriate, special audit confirms
Bayer's due diligence procedures for M&A transactions are appropriate, special audit confirmsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 23, 2020 Category: Pharmaceuticals Source Type: news
20.03.20: Not intended for U.S. and UK Media -
American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual):
Bayer announces five late-breaking presentations which include data from VICTORIA (vericiguat) and VOYAGER PAD (Xarelto™) Phase III studiesThe VICTORIA study provides insight into the efficacy of vericiguat, the first soluble guanylate cyclase (sGC) stimulator investigated in patients with chronic heart failure following a worsening event / The VOYAGER PAD study investigated the use of Xarelto 2.5 mg twice daily plus aspirin 100 mg once daily in patients with symptomatic peripheral artery disease (PAD) post peripheral revascularization / Five late-breaking abstracts have been accepted for presentation and demonstrate...
Source: Bayer IR Newsfeed: Events - March 19, 2020 Category: Pharmaceuticals Source Type: news
05.03.20: Roadshow Boston, U.S.A.
Roadshow Boston, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 4, 2020 Category: Pharmaceuticals Source Type: news
04.03.20: Roadshow New York, U.S.A.
Roadshow New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 3, 2020 Category: Pharmaceuticals Source Type: news
03.03.20: Roadshow New York, U.S.A.
Roadshow New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 2, 2020 Category: Pharmaceuticals Source Type: news
03.03.20: Roadshow London, UK
Roadshow London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - March 2, 2020 Category: Pharmaceuticals Source Type: news
